文献速递产科母胎医学

小于胎龄儿伴与不伴胎儿生长受限临床特征者的胎盘病变:DRIGITAT 研究的二次分析

Placental lesions in small for gestational age fetuses with and without clinical features of fetal growth restriction: a secondary analysis of the Doppler Ratio In fetal Growth restriction Intervention Trial At (near) Term (DRIGITAT) study.
PubMed 文献 · Am J Obstet Gynecol · 2025-05-30

该研究为 DRIGITAT 多中心前瞻性队列(含嵌套随机对照试验)的二次分析,纳入 690 例晚期早产小于胎龄儿,其中 294 例胎盘病理可评估。发现胎儿生长受限临床特征与高级别母体血管灌注不良(调整 OR 2.6,95%CI 1.7-4.2)和高级别胎儿血管灌注不良(调整 OR 1.9,95%CI 1.2-3.0)相关,两者均可产前表现为多普勒异常。

要点

  • 胎儿生长受限组高级别母体血管灌注不良占 37.8%,高于小于胎龄儿非特指组的 18.2%。
  • 高级别母体血管灌注不良与胎儿生长受限的调整 OR 为 2.6(95%CI 1.7-4.2,p<.001)。
  • 高级别母体及胎儿血管灌注不良均与复合不良围产结局显著相关。

核心结论

  • 在小于胎龄儿中,胎儿生长受限的临床特征与高级别母体血管灌注不良、高级别胎儿血管灌注不良及两者合并存在相关。
  • 这两种病变可产前表现为多普勒异常(脐脑比>0.8 或脐动脉搏动指数>p90)。

研究设计与样本

  • 本研究为 DRIGITAT 研究的二次分析,该研究为多中心前瞻性队列,含嵌套随机对照试验,纳入晚期早产小于胎龄儿妊娠。
  • 胎盘切片由 2 名对临床资料(除孕龄外)设盲的围产期病理学家独立复阅、评分和分类,依据阿姆斯特丹共识标准和 Freedman-Ernst 亚分类,使用数字综合报告工具。
  • 690 例参与者中 294 例胎盘(42.6%)可用于本分析,396 例(57.4%)无胎盘病理。
  • 参与者分为胎儿生长受限组(连续 2 次多普勒异常:脐脑比>0.8 或脐动脉搏动指数>p90 或两者均异常)、潜在胎儿生长受限组(一次或间歇性脐脑比或脐动脉搏动指数异常或两者均异常)和小于胎龄儿非特指组(从未出现脐脑比或脐动脉搏动指数异常)。
  • 采用逆概率加权校正病理样本的选择偏倚,并计算调整 OR。

主要发现

  • 病理可用组因疑似胎儿窘迫行临产前剖宫产的比例为 37.2%,显著高于病理不可用组的 11.4%。
  • 胎儿生长受限组高级别母体血管灌注不良占 37.8%,小于胎龄儿非特指组占 18.2%;高级别胎儿血管灌注不良分别占 28.9% 和 15.1%。
  • 高级别母体血管灌注不良与胎儿生长受限的调整 OR 为 2.6(95%CI 1.7-4.2;p<.001);高级别胎儿血管灌注不良的调整 OR 为 1.9(95%CI 1.2-3.0;p=.01)。
  • 高级别母体血管灌注不良和高级别胎儿血管灌注不良均与复合不良围产结局显著相关。
  • 当母体血清胎盘生长因子及可溶性 fms 样酪氨酸激酶-1:胎盘生长因子比值异常时,高级别母体血管灌注不良显著更常见。

关键数值与推荐

  • 胎儿生长受限的产前多普勒标准为连续 2 次异常测量:脐脑比>0.8 或脐动脉搏动指数>p90 或两者均异常。
  • 高级别母体血管灌注不良与胎儿生长受限的调整 OR 2.6(95%CI 1.7-4.2;p<.001)。
  • 高级别胎儿血管灌注不良与胎儿生长受限的调整 OR 1.9(95%CI 1.2-3.0;p=.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 病理可用组因疑似胎儿窘迫行临产前剖宫产的比例为 37.2%,显著高于病理不可用组的 11.4%,作者采用逆概率加权校正病理样本的选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The primary pathophysiological mechanism underlying fetal growth restriction is placental insufficiency, which can be attributed to various placental lesions. It is unknown if ultrasound markers can antenatally detect and distinguish between different placental lesions and their grading. This study aimed to investigate the association between placental lesions, clinical markers, including Doppler velocimetry, and birth outcome. STUDY DESIGN: This study was a secondary analysis of the DRIGITAT study, a multicenter prospective cohort with nested randomized controlled trial of late preterm small for gestational age pregnancies. Placental slides were independently revised, scored, and classified using a digital synoptic reporting tool, according to the Amsterdam Consensus criteria and the Freedman-Ernst subclassification, by 2 perinatal pathologists blinded to clinical data, except for gestational age. Pregnancy characteristics and birth outcomes of cases with placental pathology available were compared to those without. Within the group with pathology available, participants were classified as fetal growth restriction (2 consecutive abnormal Doppler measurements: umbilicocerebral ratio>0.8 or umbilical artery pulsatility index>p90 or both abnormal), potential fetal growth restriction (once or intermittent abnormal umbilicocerebral ratio or umbilical artery pulsatility index or both abnormal), or small for gestational age not otherwise specified (never-abnormal umbilicocerebral ratio or umbilical artery pulsatility index). Placental lesion prevalence and grading were analyzed in relation to Doppler ultrasound findings (umbilicocerebral ratio>0.8 or umbilical artery pulsatility index>p90), biomarkers (placental growth factor, and the soluble fms-like tyrosine kinase-1 placental growth factor ratio), birthweight percentiles, and composite adverse perinatal outcome. The potential relation between grading of maternal vascular malperfusion, fetal vascular malperfusion, and chronic inflammation (CI) and Doppler ultrasound and composite adverse perinatal outcome were calculated by performing a multinomial logistic regression analysis yielding a likelihood in terms of an odds ratio and 95% confidence intervals (95% CI). We used inverse probability weighting to account for selection bias in the pathology sample and adjusted odds ratios were calculated. RESULTS: Of the 690 participants, 294 placentas (42.6%) were available for this analysis, while placental pathology was unavailable for 396 participants (57.4%). Prelabor caesarean for suspected fetal distress was significantly more frequent in the group with pathology available (37.2%) compared to the group without pathology available (11.4%). In the fetal growth restriction group, 37.8% of placentas showed high-grade maternal vascular malperfusion, vs 18.2% in the small for gestational age not otherwise specified group; high-grade fetal vascular malperfusion was found in 28.9% and 15.1%, respectively. High-grade maternal vascular malperfusion was associated with the greatest odds of fetal growth restriction, with an adjusted odds ratio of 2.6 (95% CI, 1.7-4.2; p<.001). The adjusted odds ratio for high-grade fetal vascular malperfusion was 1.9 (95% CI, 1.2-3.0; p .01). Both high-grade maternal vascular malperfusion and high-grade fetal vascular malperfusion were significantly associated with composite adverse perinatal outcome. High-grade maternal vascular malperfusion was significantly more frequent if maternal serum placental growth factor and soluble fms-like tyrosine kinase-1:placental growth factor ratio were abnormal. CONCLUSION: Among the small for gestational age infants, clinical features of fetal growth restriction are associated with high-grade maternal vascular malperfusion and high-grade fetal vascular malperfusion and the combined presence of these lesions. Both lesions may manifest antenatally with Doppler abnormalities (umbilicocerebral ratio>0.8 or umbilical artery pulsatility index>p90).

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Marijnen MC, van der Meeren LE, Schoots MH, et al. Placental lesions in small for gestational age fetuses with and without clinical features of fetal growth restriction: a secondary analysis of the Doppler Ratio In fetal Growth restriction Intervention Trial At (near) Term (DRIGITAT) study. Am J Obstet Gynecol. 2025. PMID: 40451449. doi:10.1016/j.ajog.2025.05.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。